Drug intelligence / Profile preview

Cerebralcare pills placebo

Development stage: Unknown
Lead developer: Beijing Tiantan Hospital
Administration: Oral

Overview

Cerebralcare pills placebo is an inactive control substance used in clinical research, specifically within the CABLE trial (CerebrAlcare Pills on CereBral Small VesseL DiseasE) led by Beijing Tiantan Hospital. It is formulated to be indistinguishable in appearance, odor, and taste from the active Cerebralcare pills (also known as Yangxue Qingnao), which is a traditional Chinese medicine (TCM) product developed by Tasly Pharmaceutical Group. In the context of cerebral small vessel disease (CSVD), this placebo serves as a negative control to evaluate the therapeutic efficacy of the active medication on cognitive function and structural MRI markers, ensuring that observed effects are not due to the placebo effect or investigator bias.

Other names: Placebo for Yangxue QingnaoCerebralcare placebo

Beyond the preview

Go deeper on Cerebralcare pills placebo.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Cerebralcare pills placebo.